Manik Amin
Overview
Explore the profile of Manik Amin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grierson P, Suresh R, Tan B, Pedersen K, Amin M, Park H, et al.
Clin Cancer Res
. 2023 Oct;
29(23):4733-4739.
PMID: 37801295
Purpose: Vitamin D analogues remodel the desmoplastic stroma, and improve vascularity and efficacy of chemotherapy in preclinical pancreas cancer models. Patients And Methods: We conducted a pilot study to evaluate...
2.
Dhawan N, Afzal M, Amin M
Curr Oncol
. 2023 May;
30(5):4538-4550.
PMID: 37232801
The incidence and mortality of squamous cell carcinoma of the anus has been gradually increasing globally over the last few decades. The evolution of different modalities, including immunotherapies, has changed...
3.
Bergman D, Zaki L, Pettus J, Zaki B, Amin M
Thorac Cancer
. 2023 May;
14(18):1789-1792.
PMID: 37160416
Hepatocellular carcinoma (HCC) is a common cancer and is frequently diagnosed at a late and unresectable stage with limited effective treatment options. Here, we present the fifth reported case of...
4.
Deshields T, Penalba V, Arroyo C, Tan B, Tippey A, Amin M, et al.
Support Care Cancer
. 2023 May;
31(5):312.
PMID: 37126138
Purpose: Patient-reported outcomes are considered the gold standard for documenting treatment-related toxicities and cancer-related symptoms in the management of oncology patients. Poor concordance between patients and health care professionals (HCPs)...
5.
Bendell J, LoRusso P, Overman M, Noonan A, Kim D, Strickler J, et al.
Cancer Immunol Immunother
. 2023 Apr;
72(7):2443-2458.
PMID: 37016126
Background: CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with...
6.
Trikalinos N, Hammill C, Liu J, Navale P, Winter K, Chatterjee D, et al.
Abdom Radiol (NY)
. 2022 Oct;
47(12):4096-4102.
PMID: 36266515
Purpose: To determine the decision patterns of a neuroendocrine neoplasm (NEN) tumor board (TB) and the factors behind those. Methods: We retrospectively reviewed all NEN-TB recommendations from 07/2018 to 12/2021...
7.
Park R, Amin M, Trikalinos N
J Neuroendocrinol
. 2022 Jul;
34(7):e13178.
PMID: 35854663
Evidence-based recommendations for the optimal duration and sequencing of temozolomide-based treatments in advanced neuroendocrine neoplasms are lacking. Here, we conducted a systematic review of the literature for a descriptive analysis...
8.
Bagegni N, Park H, Kraft K, O-Toole M, Gao F, Waqar S, et al.
Cancer Chemother Pharmacol
. 2022 Mar;
89(4):487-497.
PMID: 35247086
Purpose: Vorolanib is a multi-target tyrosine kinase inhibitor with anti-angiogenic properties. This study aimed to evaluate the tolerability, safety and efficacy of vorolanib when added to checkpoint inhibitors (CPIs) in...
9.
Itani M, Haq A, Amin M, Mhlanga J, Lenihan D, Iravani A, et al.
Acta Radiol
. 2021 Oct;
63(9):1166-1172.
PMID: 34713716
Background: Myocardial uptake on Ga-DOTATATE PET/CT is often observed and its clinical relevance is poorly understood. Purpose: To detect any correlation between myocardial uptake of Ga-DOTATATE and presence of cardiac...
10.
Amin M, Gao F, Terrero G, Picus J, Wang-Gillam A, Suresh R, et al.
Am J Clin Oncol
. 2021 Jul;
44(9):443-448.
PMID: 34310349
Introduction: The mammalian target of rapamycin (mTOR) is a downstream mediator in the phosphatidylinositol 3-kinase/Akt signaling pathway, and plays a central role in cell proliferation, growth, differentiation, migration, and survival....